MARKET

ENLV

ENLV

Enlivex Therapeutics Ltd
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.29
+0.06
+1.15%
After Hours: 5.30 +0.01 +0.19% 17:55 07/02 EDT
OPEN
5.30
PREV CLOSE
5.23
HIGH
5.41
LOW
5.18
VOLUME
64.19K
TURNOVER
--
52 WEEK HIGH
44.90
52 WEEK LOW
3.590
MARKET CAP
71.03M
P/E (TTM)
-7.0912
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ENLV stock price target is 22.00 with a high estimate of 22.00 and a low estimate of 22.00.

EPS

ENLV News

More
GNW, WKHS, ZYNE and BE among midday movers
Seeking Alpha - Article · 3d ago
Enlivex Announces Allowance of New Japanese Patent Application Covering ALLOCETRA Immunotherapy
Nes-Ziona, Israel, June 18, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company, today announced that the Japan Patent Office (JPO) has issued a notice of allowance for a patent application covering ALLOCETRATM, the co
GlobeNewswire · 06/18 12:30
Enlivex Therapeutics to Present at the Jefferies 2020 Virtual Healthcare Conference
GlobeNewswire · 06/01 13:00
Enlivex Presents New Clinical Data Demonstrating Early Resolution of Cytokine Storms in Sepsis Patients Treated with Allocetra at the International Society for Cellular Therapy 2020 Paris Virtual Annual Meeting
GlobeNewswire · 05/28 13:30
Enlivex's Allocetra shows potential for resolving out-of-control immune responses
Seeking Alpha - Article · 05/28 12:58
We're Not Very Worried About Enlivex Therapeutics's (NASDAQ:ENLV) Cash Burn Rate
Simply Wall St. · 05/20 11:56
RIG, OKE among premarket gainers
Seeking Alpha - Article · 04/13 13:21
Enlivex reports final data from study of Allocetra in severe sepsis
Seeking Alpha - Article · 03/18 15:28

Industry

Biotechnology & Medical Research
+0.67%
Pharmaceuticals & Medical Research
+0.61%

Hot Stocks

Symbol
Price
%Change

About ENLV

Enlivex Therapeutics Ltd is an Israel-based clinical-stage company focused on specialized cell immunotherapy. The Company aims to develop and commercialize an allogeneic drug pipeline for rebalancing all manner of immune hyper-responses. The Company is developing Allocetra, a cell-based immunotherapy, for the treatment of numerous acute conditions. It rebalances a life-threatening unbalanced immune system, using the immune system’s own natural regulation mechanisms. Allocetra is designed to avert cytokine storms and restores safe immune balance, without suppressing the immune system, by engaging macrophages and dendritic cells. The Company’s clinical development programs focus on preventing or treating complications associated with bone-marrow transplantations, Sepsis and solid tumors.
More

Webull offers kinds of Enlivex Therapeutics Ltd stock information, including NASDAQ:ENLV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENLV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ENLV stock methods without spending real money on the virtual paper trading platform.